A healthcare-focused hedge fund placed $24.5 million into Immunovant during the quarter ending December 31, lifting the autoimmune biotech name to 2.11% of the fund's 13F-reportable assets. The filing landed March 14. The fund disclosed $1.16 billion in reportable long positions across 47 securities, with the Immunovant stake now the third-largest disclosed holding by percentage weight.
The deployment sits beneath two anchor positions: Revolution Medicines at $238.5 million (14.4% of AUM) and Prax at $110.53 million (6.7% of AUM). The concentration tells its own story. The fund runs a conviction book. Immunovant, a clinical-stage developer targeting FcRn biology for autoimmune indications, entered the portfolio during a quarter when the stock traded between $32 and $47 per share. The fund's cost basis remains undisclosed, but the position size implies roughly 600,000 to 750,000 shares depending on entry timing. Immunovant closed March 14 at $41.22, yielding a portfolio value near the filed amount if the stake was built near quarter-end.
The fund's 13F architecture matters because it reveals sector-specific risk appetite. The top three holdings represent 23.21% of reportable AUM, a narrow concentration unusual among generalist funds but standard for specialist healthcare vehicles. Immunovant's inclusion at 2.11% suggests conviction without recklessness — enough to move on data, not enough to destabilize the book if trials disappoint. The company's lead asset, batoclimab, posted Phase 3 data in myasthenia gravis during late 2024, with dosing convenience and subcutaneous administration as differentiation points against intravenous FcRn competitors. The fund's entry timing aligns with post-data positioning, when clinical risk compresses but commercial risk expands.
Allocators should watch three catalysts over the next six to nine months. First, Immunovant's regulatory filing timeline for batoclimab in myasthenia gravis, expected mid-2026 if the company maintains its stated cadence. Second, data readouts from ongoing trials in thyroid eye disease and chronic inflammatory demyelinating polyneuropathy, both of which could widen the addressable market and justify the current $5.8 billion market capitalization. Third, any 13G filings from other healthcare specialists, which would confirm whether this $24.5 million move reflects isolated conviction or early-stage sector rotation into FcRn plays. The fund's willingness to deploy at 2.11% weight — larger than 80% of its disclosed book — suggests it sees asymmetry.
Immovant's burn rate and cash runway also matter. The company held $738 million in cash and equivalents as of its last 10-Q, sufficient for roughly 24 months at current operating expense. The fund's entry assumes either regulatory success before cash pressure or a secondary offering into strength, neither of which carries certainty. The stock's 47% rise over the prior twelve months before the filing period ended means the fund entered momentum, not distress. That shift — from bottom-fishing to momentum-chasing in biotech — marks a subtle change in healthcare allocator behavior worth noting. The fund now owns 2.11% of its book in a name that needs two more things to work: FDA approval and commercial execution. One without the other destroys value.